QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 限定条件 发表日期：2022     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors (vol 0, pg 1, 2022) 期刊论文 ACTA PHARMACOLOGICA SINICA, 2022 作者:  Cao, Guo-zhen;  Ma, Li-ying;  Zhang, Zong-hui;  Wang, Xiao-lin;  Hua, Jing-han 收藏  |  浏览/下载：21/0  |  提交时间：2022/12/23 Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors 期刊论文 ACTA PHARMACOLOGICA SINICA, 2022 作者:  Cao, Guo-Zhen;  Ma, Li-Ying;  Zhang, Zong-Hui;  Wang, Xiao-Lin;  Hua, Jing-Han 收藏  |  浏览/下载：23/0  |  提交时间：2022/12/22 small-cell lung cancer  H3  3  PARP1  PARP inhibitor  darinaparsin  combination treatment   Vanguard is a Glucose Deprivation-Responsive Long Non-Coding RNA Essential for Chromatin Remodeling-Reliant DNA Repair 期刊论文 ADVANCED SCIENCE, 2022 作者:  Zhang, Ben;  Thorne, Rick Francis;  Zhang, Pengfei;  Wu, Mian;  Liu, Lianxin 收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23 genomic stability  HMGB1  long non-coding RNAs  PARP inhibitors  Vanguard   Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文 BMC CANCER, 2022, 卷号: 22 作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong 收藏  |  浏览/下载：18/0  |  提交时间：2022/12/23 Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib   Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial 期刊论文 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022 作者:  Liu, Jihong;  Yin, Rutie;  Wu, Lingying;  Zhu, Jianqing;  Lou, Ge 收藏  |  浏览/下载：30/0  |  提交时间：2022/05/05 BRCA mutation  China  olaparib  ovarian cancer  PARP inhibitor   Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study 期刊论文 CLINICAL CANCER RESEARCH, 2022, 卷号: 28 作者:  Wu, Xiaohua;  Zhu, Jianqing;  Wang, Jing;  Lin, Zhongqiu;  Yin, Rutie 收藏  |  浏览/下载：102/0  |  提交时间：2022/03/28